SCD and Gene Therapy: Additional facts about the LentiGlobin Study #Lyfgenia #GeneTherapy #CRISPRGeneEditing #SickleCellDisease #Hematology #CellTherapy #RareDiseases #BloodDisorders #MedicalEducation #InternalMedicine

🧬 Today’s question explores how clinical trials classify post-treatment deaths in assessing the safety profile of gene therapy. See the answer and explanation on the next slide! #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #ClinicalTrials #RareDiseases #BloodDisorders #MedicalEducation

SCD and Gene Therapy: Additional facts about the LentiGlobin Study @asgct.bsky.social @ash.edu.hematology.org @ash.hematology.org @cuhemeonc.bsky.social @bsochaem.bsky.social #Lyfgenia #LentiGlobin #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #MedicalEducation #InternalMedicine

🧬 Today’s question focuses on how #Lyfgenia differs from allogeneic #HSCT. See the answer and explanation on the next slide! @asgct.bsky.social @ash.edu.hematology.org @bsochaem.bsky.social @dukemedschool.bsky.social @dgsomucla.bsky.social @harvardmed.bsky.social @bcmhouston.bsky.social

SCD and Gene Therapy: Additional facts about the LentiGlobin Study @asgct.bsky.social @bsochaem.bsky.social @ash.edu.hematology.org @ash.hematology.org @cuhemeonc.bsky.social @ucsdmedschool.bsky.social @bcmhouston.bsky.social @dukemedschool.bsky.social @dgsomucla.bsky.social #Hematology

🧬 Today’s question explores how the lasting success of gene therapy is assessed beyond symptom resolution. See the answer and explanation on the next slide! @asgct.bsky.social @ash.edu.hematology.org @bsochaem.bsky.social @ash.hematology.org @vjhemonc.bsky.social @sicklecelluk.bsky.social

Case submissions are a vital part of our educational seminars. You can submit cases directly on our website! 🩸Highlight real-world diagnostic challenges and share knowledge that supports education across all levels. Visit hemehub.org to learn more! #Hematology #MedicalEducation

SCD and Gene Therapy: Additional facts about the LentiGlobin Study @ash.hematology.org @asgct.bsky.social @ash.edu.hematology.org #Lyfgenia #LentiGlobin #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #ClinicalTrials #RareDiseases #BloodDisorders #StemCellTherapy

Facts about Sickle Cell Disease and Gene Therapy Study Focus: LentiGlobin (Lovotibeglogene Autotemcel, Lyfgenia) @ash.hematology.org @asgct.bsky.social @ash.edu.hematology.org #Lyfgenia #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #RareDiseases #BloodDisorders #MedicalEducation

Today’s question! Check out the answer on the next slide along with its explanation. #Lyfgenia #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #RareDiseases #BloodDisorders @ash.hematology.org @rarediseasectn.bsky.social @cuhemeonc.bsky.social @ash.edu.hematology.org @asgct.bsky.social

Why might anemia persist in a patient treated with Lyfgenia despite elimination of VOCs? See the answer and explanation on the next slide! #Lyfgenia #LentiGlobin #GeneTherapy #SickleCellDisease #Hematology #CellTherapy #ClinicalTrials #RareDiseases #BloodDisorders #StemCellTherapy

Today’s question explores how vector copy number relates to treatment outcomes in patients receiving Lyfgenia. Check out the answer on the next slide along with its explanation! #Lyfgenia #GeneTherapy #SickleCellDisease #Hematology #RareDiseases #BloodDisorders #MedicalEducation

Facts about #SickleCellDisease and #GeneTherapy Study Focus: #LentiGlobin The HGB-206 clinical trial refined the treatment process, including transfusion regimens, busulfan conditioning, and manufacturing methods, leading to improved and consistent outcomes for patients with sickle cell disease.

Today’s question highlights the clinical effects of Lyfgenia™ in a patient with SCD. Check out the answer on the next slide along with its explanation! @ascaa.bsky.social @sicklecell101.bsky.social @sicklecelluk.bsky.social @asgct.bsky.social #SickleCellDisease #Hematology #BloodDisorders

An overview of Lyfgenia and the antisickling hemoglobin HbAT87Q, highlighting the mechanism by which autologous stem cells are engineered to restore functional red blood cells. @ascaa.bsky.social @sicklecell101.bsky.social @sicklecelluk.bsky.social #SickleCellDisease #Hematology #CellTherapy

This Month on HemeHub: SCD and Gene Therapy Join us as we explore advances in the treatment of #sicklecelldisease through #genetherapy, featuring pivotal trials of Lyfgenia and Casgevy. Stay tuned for our upcoming session featuring Dr. John Tisdale, Senior Investigator at the NHLBI.

Today's second question is about the diagnostic approach to JAK2-unmutated #erythrocytosis and the appropriate next step in evaluation. The third question focuses on the mechanism by which HFE mutations contribute to #erythrocytosis. Check out the answers to both questions on the next slides!

Today’s first question highlights a key distinguishing feature of TEMPI syndrome in clinical practice. #JAK2NegativeErythrocytosis #NonPVErythrocytosis #Erythrocytosis #Hematology #MyeloproliferativeDisorders #SecondaryErythrocytosis #EPO #Hypoxia #GermlineMutations #ClinicalHematology

Facts about JAK2 unmutated erythrocytosis: Genetic variants in Epo signaling, oxygen affinity, and iron metabolism can all contribute to inherited erythrocytosis. @bsochaem.bsky.social @ash.edu.hematology.org @vjhemonc.bsky.social @rarediseasectn.bsky.social #Erythrocytosis #Hematology

Today’s question is about the complications of erythrocytosis in congenital heart disease and their underlying associations. #JAK2NegativeErythrocytosis #Erythrocytosis #Hematology @bsochaem.bsky.social @vjhemonc.bsky.social @ash.hematology.org @ash.edu.hematology.org @cuhemeonc.bsky.social

Facts about JAK2 unmutated erythrocytosis: The HIF-PHD-VHL pathway, driven by HIF2A, links oxygen and iron sensing to Epo production and hypoxia-induced erythrocytosis. @vjhemonc.bsky.social @ash.hematology.org @ash.edu.hematology.org @bsochaem.bsky.social #Erythrocytosis #Hematology

Missed our session with Dr. Naseema Gangat on JAK2 Unmutated Erythrocytosis? The full recording is now available on our YouTube channel! ➡️Watch the full session: www.youtube.com/watch?si=Qeq... @bsochaem.bsky.social @vjhemonc.bsky.social @cuhemeonc.bsky.social @bsochaem.bsky.social #Hematology

Today’s question is about evaluating causes of erythrocytosis in a JAK2-negative patient with menorrhagia. Check out the answer on the next slide along with its explanation! @ash.edu.hematology.org @stanfordmedicine.bsky.social @bcmhouston.bsky.social @medicine.stitches.today @bsochaem.bsky.social

Facts about JAK2 unmutated erythrocytosis: Post-renal transplant erythrocytosis declines with ACEi/ARBs; management is monitoring and CV risk control, not routine phlebotomy or JAK2 inhibitors. #JAK2NegativeErythrocytosis #Erythrocytosis #Hematology #MyeloproliferativeDisorders

Today’s question is about predisposing factors for erythrocytosis. Check out the answer on the next slide along with its explanation! @ash.edu.hematology.org @stanfordmedicine.bsky.social @bcmhouston.bsky.social @yaleschoolofmed.bsky.social @medicine.stitches.today @dukemedschool.bsky.social

Facts about JAK2-unmutated erythrocytosis: How SGLT-2 inhibitors and testosterone therapy can raise hemoglobin/hematocrit and what current guidelines recommend for management. #Hematology @ash.edu.hematology.org @rarediseasectn.bsky.social @bsochaem.bsky.social @vjhemonc.bsky.social

Today’s question! Check out the answer on the next slide along with its explanation. @vjhemonc.bsky.social @bsochaem.bsky.social @ash.edu.hematology.org @rarediseasesint.bsky.social @ucsdmedschool.bsky.social @stanfordmedicine.bsky.social @bcmhouston.bsky.social @cuhemeonc.bsky.social

Facts about JAK2 unmutated erythrocytosis: In Chuvash polycythemia and high oxygen affinity hemoglobin, thrombosis risk is linked to age and cardiovascular factors—not hematocrit—and phlebotomy or hydroxyurea are generally not beneficial. #Erythrocytosis #Hematology #MyeloproliferativeDisorders

Facts about JAK2-unmutated erythrocytosis: Phlebotomy isn’t recommended for asymptomatic patients, may be harmful in physiologic cases, and can cause its own side effects. @ash.edu.hematology.org @vjhemonc.bsky.social @rarediseasectn.bsky.social @bsochaem.bsky.social @ash.hematology.org

Today’s question! Check out the answer on the next slide along with its explanation. #Hematology #Medicine #Erythrocytosis #MyeloproliferativeDisorders @ash.edu.hematology.org @bsochaem.bsky.social @rarediseasectn.bsky.social @rarediseasesint.bsky.social @ash.hematology.org @vjhemonc.bsky.social

Today’s question! Check out the answer on the next slide along with its explanation. @vjhemonc.bsky.social @ash.edu.hematology.org @bsochaem.bsky.social @rarediseasectn.bsky.social @rarediseasesint.bsky.social @yaleschoolofmed.bsky.social @dukemedschool.bsky.social @cuhemeonc.bsky.social

Facts about JAK2-unmutated erythrocytosis: Management & Treatment @vjhemonc.bsky.social @bsochaem.bsky.social @ash.edu.hematology.org @rarediseasectn.bsky.social @rarediseasesint.bsky.social @ucsdmedschool.bsky.social @cuhemeonc.bsky.social @stanfordmedicine.bsky.social @bcmhouston.bsky.social

Today’s question! Check out the answer on the next slide along with its explanation. @ash.edu.hematology.org @rarediseasectn.bsky.social @rarediseasesint.bsky.social @bsochaem.bsky.social @vjhemonc.bsky.social #Erythrocytosis #Hematology #MyeloproliferativeDisorders #SecondaryErythrocytosis #EPO

Facts about JAK2 Unmutated Erythrocytosis: Treatment isn’t based on strong evidence, and phlebotomy is mainly for symptom control. @ash.edu.hematology.org @bsochaem.bsky.social @vjhemonc.bsky.social @rarediseasectn.bsky.social @rarediseasesint.bsky.social

Today’s question! Check out the answer on the next slide along with its explanation. #JAK2NegativeErythrocytosis #NonPVErythrocytosis #Erythrocytosis #Hematology @ash.edu.hematology.org @bsochaem.bsky.social @vjhemonc.bsky.social @rarediseasectn.bsky.social @rarediseasesint.bsky.social

Facts about JAK2 Unmutated Erythrocytosis: Disease Overview and Diagnosis @ash.edu.hematology.org@vjhemonc.bsky.social @bsochaem.bsky.social @ucsdmedschool.bsky.social @bcmhouston.bsky.social @yaleschoolofmed.bsky.social @yaleschoolofmed.bsky.social @medicine.stitches.today @cuhemeonc.bsky.social

Case submissions are a vital part of our educational seminars. You can now submit cases directly on our website. ➡️Visit hemehub.org to learn more! @ash.edu.hematology.org @vjhemonc.bsky.social @bsochaem.bsky.social @rarediseasectn.bsky.social @rarediseasesint.bsky.social @ash.hematology.org

Today’s second question! Check out the answer on the next slide along with its explanation. @ash.edu.hematology.org @ucsdmedschool.bsky.social @stanfordmedicine.bsky.social @bcmhouston.bsky.social @yaleschoolofmed.bsky.social @medicine.stitches.today @dgsomucla.bsky.social

Today's first question is about erythrocytosis linked to elevated EPO from renal pathology. Check out the answer on the next slide along with its explanation! @vjhemonc.bsky.social @ash.hematology.org @ash.edu.hematology.org @bsochaem.bsky.social #hematology #erythrocytosis #pathology #medical

🩸Speaker Update Our upcoming webinar on JAK2 Negative Erythrocytosis will now feature Dr. Naseema Gangat, Professor of Medicine and Consultant Hematologist at Mayo Clinic. You can submit your own cases for the upcoming sessions at: hemehub.org/case-submiss... Register now: hemehub.org/live-events

Today’s question! Check out the answer on the next slide along with its explanation. #NonPVErythrocytosis #Erythrocytosis #Hematology #MyeloproliferativeDisorders #SecondaryErythrocytosis @vjhemonc.bsky.social @bsochaem.bsky.social @ash.edu.hematology.org

Facts about JAK2 Unmutated Erythrocytosis: Erythrocytosis can stem from germline oxygen-sensing mutations, HFE variants, renal tumors making Epo, or rare syndromes like TEMPI. #Erythrocytosis #Hematology @vjhemonc.bsky.social @ash.hematology.org @bsochaem.bsky.social @ash.edu.hematology.org

Facts about JAK2 Unmutated Erythrocytosis: In hereditary erythrocytosis, HOAV can explain normal/high Epo. Modern labs use HPLC and mass spectrometry instead of P50. PIEZO1 mutations expand the genetic spectrum. #Erythrocytosis #Hematology #MyeloproliferativeDisorders

Today’s question! Check out the answer on the next slide along with its explanation. #Erythrocytosis #Hematology #MyeloproliferativeDisorders #Hematology #Hypoxia @bsochaem.bsky.social @ash.edu.hematology.org @vjhemonc.bsky.social @uthealthsa.bsky.social

Facts about JAK2 Unmutated Erythrocytosis: Epo levels guide diagnosis, marrow biopsy shows MPN, RCM is limited, and genetics matter in youth. #Erythrocytosis #Hematology #Hypoxia @dukemedschool.bsky.social @dgsomucla.bsky.social @einsteinmededu.bsky.social @bcmhouston.bsky.social

Facts about JAK2-unmutated erythrocytosis: More common than PV, confirmed with repeat blood counts, ruled out by JAK2 testing, and classified as hereditary or acquired. @dukemedschool.bsky.social @dgsomucla.bsky.social @einsteinmededu.bsky.social @bcmhouston.bsky.social @harvardmed.bsky.social

Today’s question! Check out the answer on the next slide along with its explanation. #JAK2NegativeErythrocytosis #Erythrocytosis #Hematology #MyeloproliferativeDisorders @vjhemonc.bsky.social @ash.hematology.org @ash.edu.hematology.org @bsochaem.bsky.social @isbt.bsky.social

This Month on HemeHub: JAK2 Unmutated Erythrocytosis Join us as we highlight essential insights on the diagnosis, management, and treatment of JAK2 Unmutated Erythrocytosis. #Hematology #BloodDisorders #SecondaryErythrocytosis @bsochaem.bsky.social @vjhemonc.bsky.social @ash.edu.hematology.org

Exciting update from HemeHub! Our website has been enhanced for simpler access to live events, cases, webinars, and more. Check it out today and experience what’s new! #Hematology #MedicalEducation #LiveEvents #InteractiveLearning @ash.hematology.org @bsochaem.bsky.social @vjhemonc.bsky.social

Join us for an exclusive webinar with Dr. Ayalew Tefferi, professor of Hematology and Medicine at Mayo Clinic and a leading expert in chronic myeloproliferative neoplasms. Register now: hemehub.org/live-events @ash.edu.hematology.org @nejm.org @vjhemonc.bsky.social @bsochaem.bsky.social